One‐Year Outcomes After Intravenous Recombinant Tissue Plasminogen Activator for Ischemic Stroke: A Real‐World Study
Authors
- Rui Xue
- Shenqiang Yan (ORCID: https://orcid.org/0000-0001-6425-0672)
- Wansi Zhong (ORCID: https://orcid.org/0000-0002-4775-7778)
- Changzheng Yuan (ORCID: https://orcid.org/0000-0002-2389-8752)
- Zhicai Chen (ORCID: https://orcid.org/0000-0003-4937-6749)
- Min Lou (ORCID: https://orcid.org/0000-0002-6627-064X)
- Xiaoxian Gong (ORCID: https://orcid.org/0000-0002-0047-1246)
- Yu-Hui Huang (ORCID: https://orcid.org/0000-0001-6664-2442)
- Y. Chen (ORCID: https://orcid.org/0000-0003-4443-1921)
- Haitao Hu (ORCID: https://orcid.org/0000-0002-4656-7251)
- Haidi Jin (ORCID: https://orcid.org/0009-0001-5658-3087)
Institutions
- Harvard University (US)
- Second Affiliated Hospital of Zhejiang University (CN)
Publication Details
- Journal
- CNS Neuroscience & Therapeutics
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1111/cns.70543
- Citations
- 3
- Primary Topic
- Acute Ischemic Stroke Management
- Type
- article
- Field-Weighted Citation Impact
- 4.06
Funders
- Boehringer Ingelheim
- National Natural Science Foundation of China
- National Health Commission of the People's Republic of China